Loxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis (Loxo Oncology Inc)
(WorldNews Health)

(Source: Loxo Oncology Inc) STAMFORD, Conn., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company has completed clinical trial enrollment for the larotrectinib New Drug Application (NDA) primary efficacy analysis. This determination is based on written feedback from the U.S. Food and Drug Administration (FDA), which affirmed the target enrollment goal for the primary efficacy analysis data set to support an NDA filing. All larotrectinib clinical trials will remain open to provide a mechanism for drug access to...